...Carole Rouiller-Braunschweig; Nicolas Fournier; Valérie Pittet; Jean Dudler; Pierre Michetti Background/Aims: Evidence for the effectiveness of methotrexate (MTX) in treating inflammatory bowel disease (IBD) is still incomplete. This study assessed the effectiveness, safety and mucosal healing...

... before and after treatment with methotrexate, a potentially hepatotoxic drug) by immunohistochemical methods. Histologically normal liver biopsies from patients undergoing abdominal surgery served as normal controls. Hepatic parenchymal nerves were absent in cirrhotic nodules and were depleted...

... were not significantly changed in leukemic mice in comparison to normal mice. The mitotic activity and the depth of the crypt 48 h after 20 mg methotrexate (MTX)/kg were significantly reduced (p < 0.01) in leukemic mice. Sucrase (p < 0.001) and maltase (p < 0.025) activities in the jejunum...

...Igor Sukhotnik; Jorge G. Mogilner; Rahel Karry; Benhoor Shamian; Michael Lurie; Natalie Kokhanovsky; Benno M. Ure; Arnold G. Coran Background/Aims: The objective of this study was to evaluate the effects of oral glutamine in preventing intestinal mucosal damage caused by methotrexate (MTX) in rats...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2008 Crohn&#8217;s disease Fistula Antibiotics Azathioprine Infliximab Methotrexate Cyclosporine Tacrolimus Internal fistulas, surgery...

... for patients who continued with the therapy for up to 5 years. Methotrexate has also been found to be effective in maintaining remission in Crohn’s disease in patients who have responded acutely to methotrexate. Cyclosporine has not been found to be an effective maintenance agent. Only a few studies in small...

... or in whom steroids are contraindicated. Purine analogues, methotrexate and infliximab have all shown efficacy in achieving steroid-free remission in patients with steroid-refractory or steroid-dependent disease. Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated...

... (azathioprine and 6-mercaptopurine) are the most efficient and used immunomodulators in IBD; steroid refractoriness, steroid dependency, and long-term maintenance of remission for both UC and CD are their main indications. Methotrexate and infliximab may be used in the same clinical settings as thiopurines...

.... Immunomodulators such as azathioprine/6-mercaptopurine or methotrexate should be given early in the disease. In the case of resistance to immunomodulators, infliximab should be given. Cyclosporin A or tacrolimus should be tried in patients who fail to respond to infliximab. References 1. Sandborn WJ, et al...

..., review Crohn&#8217;s disease, therapy Aminosalicylates Steroids Azathioprine Methotrexate Infliximab Several drugs have been evaluated for the treatment of luminal Crohn’s disease (CD), the classical form of the disease. Therapeutic recommendations depend upon the disease location...

... steroids are contraindicated. Purine analogues, methotrexate and infliximab have shown efficacy in achieving steroid-free remission in patients with steroid-refractory or -dependent disease. Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Nataluzimab may...

... for this indication. Azathioprine and 6-mercaptopurine are effective in maintaining remission. Maintenance benefits remain significant for patients who continued with the therapy for up to 5 years. Methotrexate has also been found to be effective in maintaining remission in Crohn’s disease in patients who have...